Skip to content

Cervical Cancer Health Center

Medical Reference Related to Cervical Cancer

  1. Gestational Trophoblastic Disease Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Stage Information for Gestational Trophoblastic Disease

    Hydatidiform Mole (HM)HM (molar pregnancy) is disease limited to the uterine cavity. Gestational Trophoblastic NeoplasiaDefinitions: FIGOThe Féderation Internationale de Gynécologie et d'Obstétrique (FIGO) and the American Joint Committee on Cancer (AJCC) have designated staging to define gestational trophoblastic neoplasia; the FIGO system is most commonly used.[1,2] Some tumor registrars encourage the recording of staging in both systems.FIGO staging system (and modified World Health Organization [WHO] prognostic scoring system)The FIGO staging system is as follows:[1]Table 1. Gestational Trophoblastic Neoplasia (GTN)a,bFIGO Anatomical StagingFIGO = Féderation Internationale de Gynécologie et d'Obstétrique; hCG = human chorionic gonadotropin; iu = international unit; WHO = World Health Organization.a Adapted from FIGO Committee on Gynecologic Oncology.[1]b To stage and allot a risk factor score, a patient's diagnosis is allocated to a stage as

  2. Gestational Trophoblastic Disease Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Get More Information From NCI

    Call 1-800-4-CANCERFor more information, U.S. residents may call the National Cancer Institute's (NCI's) Cancer Information Service toll-free at 1-800-4-CANCER (1-800-422-6237) Monday through Friday from 8:00 a.m. to 8:00 p.m., Eastern Time. A trained Cancer Information Specialist is available to answer your questions.Chat online The NCI's LiveHelp® online chat service provides Internet users with the ability to chat online with an Information Specialist. The service is available from 8:00 a.m. to 11:00 p.m. Eastern time, Monday through Friday. Information Specialists can help Internet users find information on NCI Web sites and answer questions about cancer. Write to usFor more information from the NCI, please write to this address:NCI Public Inquiries Office9609 Medical Center Dr. Room 2E532 MSC 9760Bethesda, MD 20892-9760Search the NCI Web siteThe NCI Web site provides online access to information on cancer, clinical trials, and other Web sites and organizations that offer support

  3. Cervical Cancer Screening (PDQ®): Screening - Health Professional Information [NCI] - nci_ncicdr0000062756-nci-header

    This information is produced and provided by the National Cancer Institute (NCI). The information in this topic may have changed since it was written. For the most current information, contact the National Cancer Institute via the Internet web site at http://cancer.gov or call 1-800-4-CANCER.Cervical Cancer Screening

  4. Endometrial Cancer Screening (PDQ®): Screening - Health Professional Information [NCI] - Summary of Evidence

    Separate PDQ summaries on Prevention of Endometrial Cancer; Endometrial Cancer Treatment; and Uterine Sarcoma Treatment are also available. Benefits There is inadequate evidence that screening by ultrasonography (e.g.,transvaginal ultrasound [TVU]) or endometrial sampling would reduce the mortality from endometrial cancer. Description of the Evidence STUDY DESIGN: No studies have adequately ...

  5. Endometrial Cancer Screening (PDQ®): Screening - Health Professional Information [NCI] - Questions or Comments About This Summary

    If you have questions or comments about this summary, please send them to Cancer.gov through the Web site's Contact Form. We can respond only to email messages written in English.

  6. Cervical Cancer Treatment (PDQ®): Treatment - Health Professional Information [NCI] - nci_ncicdr0000062759-nci-header

    This information is produced and provided by the National Cancer Institute (NCI). The information in this topic may have changed since it was written. For the most current information, contact the National Cancer Institute via the Internet web site at http://cancer.gov or call 1-800-4-CANCER.Cervical Cancer Treatment

  7. Endometrial Cancer Screening (PDQ®): Screening - Health Professional Information [NCI] - Significance

    Epidemiology of Endometrial CancerIncidence and mortalityEndometrial cancer is the most common invasive gynecologic cancer in U.S. women, with an estimated 49,560 new cases expected to occur in 2013 and an estimated 8,190 women expected to die of the disease.[1] Endometrial cancer is primarily a disease of postmenopausal women with a mean age at diagnosis of 60 years.[2] Age-adjusted endometrial cancer incidence in the United States has declined since 1975, with a transient increase in incidence occurring from 1973 to 1978, which was associated with estrogen therapy, also known as hormone therapy;[3] there was no associated increase in mortality. From 2005 to 2009, incidence rates of endometrial cancer were stable in white women but increased in African American women by 2.2% per year.[1] The endometrial cancer mortality rates are stable in white women but increased slightly (by 0.4% per year) in African American women from 2005 to 2009.[1] Most cases of endometrial cancer are

  8. Gestational Trophoblastic Disease Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Recurrent or Chemoresistant Gestational Trophoblastic Neoplasia Treatment

    Recurrent disease indicates failure of prior chemotherapy unless initial therapy was surgery alone. One study found recurrence of disease in 2.5% of patients with nonmetastatic disease, 3.7% of patients with good-prognosis metastatic disease, and 13% of patients with poor-prognosis metastatic disease.[1] Nearly all recurrences occur within 3 years of remission (85% before 18 months). A patient whose disease progresses after primary surgical therapy is generally treated with single-agent chemotherapy unless one of the poor-prognosis factors that requires combination chemotherapy supervenes. Relapse after prior chemotherapy failure automatically places the patient into the high-risk category. These patients should be treated with aggressive chemotherapy. Reports of combination chemotherapy come from small retrospective case series. Long-term disease-free survival, in excess of 50%, is achievable with combination drug regimens.[2][Level of evidence: 3iiiDii] A variety of regimens have

  9. Cervical Cancer Screening (PDQ®): Screening - Patient Information [NCI] - Risks of Cervical Cancer Screening

    Screening tests have risks.Decisions about screening tests can be difficult. Not all screening tests are helpful and most have risks. Before having any screening test, you may want to discuss the test with your doctor. It is important to know the risks of the test and whether it has been proven to reduce the risk of dying from cancer.The risks of cervical cancer screening include the following: False-negative test results can occur.Screening test results may appear to be normal even though cervical cancer is present. A woman who receives a false-negative test result (one that shows there is no cancer when there really is) may delay seeking medical care even if she has symptoms.False-positive test results can occur.Screening test results may appear to be abnormal even though no cancer is present. Also, some abnormal cells in the cervix never become cancer. A false-positive test result (one that shows there is cancer when there really isn't) can cause anxiety and is usually followed by

  10. Endometrial Cancer Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Treatment Option Overview

    Patients with endometrial cancer who have localized disease are usually curable by hysterectomy and bilateral salpingo-oophorectomy. Best results are obtained with either of two standard treatments: hysterectomy or hysterectomy and adjuvant radiation therapy (when deep invasion of the myometrial muscle [50% of the depth] or grade 3 tumor with myometrial invasion is present). Results of two randomized trials on the use of external-beam radiation therapy (EBRT) in patients with stage I disease did not show improved survival but did show reduced locoregional recurrence (3%–4% vs. 12%–14% after 5–6 years' median follow-up, P 50% myometrial invasion or grade 3 with <50% myometrial invasion).[4]Vaginal cuff

Displaying 111 - 120 of 159 Articles << Prev Page 10 11 12 13 14 15 16 Next >>

Today on WebMD

cancer cell
HPV is the top cause. Find out more.
doctor and patient
Get to know the Symptoms.
 
sauteed cherry tomatoes
Fight cancer one plate at a time.
Lung cancer xray
See it in pictures, plus read the facts.
 
Integrative Medicine Cancer Quiz
QUIZ
Lifestyle Tips for Depression Slideshow
SLIDESHOW
 
Screening Tests for Women
Slideshow
what is your cancer risk
HEALTH CHECK